pharma news today glp-1 obesity drug updates Some US employers to drop coverage of drugs in 2027 as use increases Dozens of new obesity drugs

These medications target receptors in the brain specifically in the hypothalamus and hindbrain to curb appetite and reduce constant thoughts about food, often referred to as "food noise." "Lots of people describe it as decreasing food noise, which means how much you think about food and how much you crave different foods." Evan Nadler, MD, MBA, Adjunct Associate Professor, George Washington University Myth 5: GLP-1 Medications Are Only for Type 2 Diabetes Although GLP-1 medications were initially created to manage diabetes, they now have FDA approval for chronic weight management in people without diabetes

We speculate that these effects of GSSG are attributable, at least partly, to the anti-aging action of GSH, because GSSG is converted to GSH in the skin

Makeup (February 2025 to January 2026) Subtle, natural-looking makeup continues to be popularized by medium-coverage products such as concealers

Innovative Press & Shake Design: Ensures ingredients are kept fresh until the moment of use, giving you a practical and easy experience anytime, anywhere

However, dysfunctional mitochondria are associated with impaired neuronal function and associated neurodegenerative diseases (187)

employed a diet-induced NASH mouse model to compare the efficacy of cotadutide (a dual GLP-1/GCG agonist) against liraglutide (selective GLP-1 receptor agonist) and pair-fed controls